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We compared estimated costs of retesting human immuno-
deficiency virus (HIV)-positive persons before antiretroviral 
therapy (ART) initiation to the costs of ART provision to mis-
diagnosed HIV-negative persons. Savings from averted unnec-
essary ART costs were greater than retesting costs within 1 year 
using assumptions representative of HIV testing performance 
in programmatic settings. Countries should implement re-test-
ing before ART initiation.
Keywords. HIV testing; misdiagnosis; antiretroviral treat-
ment; cost-benefit analysis.
 
New guidelines from the World Health Organization (WHO) 
recommend antiretroviral therapy (ART) for all people with 
human immunodeficiency virus (HIV) irrespective of disease 
status [1]. This recommendation underscores the importance of 
HIV testing quality to ensure that only people living with HIV 
are placed on lifelong treatment.
Current WHO guidance recommends independent retest-
ing to verify HIV infection prior to ART initiation, and the 
WHO have and recently reemphasized this as ART programs 
have rapidly expanded [2–5]. However, this recommenda-
tion is poorly implemented: a 2015 review found that only 2 
out of 48 national HIV testing policies stated that retesting 
should be carried out before ART initiation [6]. Limited 
uptake of this recommendation may be due to a perceived 
high cost of retesting, overstretched health workers and 
system capacity, and uncertainty about how to implement 
retesting.
The risk of misclassification resulting in initiating HIV-
negative people on ART is not hypothetical [7, 8]. In Malawi, 
4.6% of people referred for ART in 2015 were subsequently 
found to be HIV-negative when retested [9]. In Zimbabwe, 
77 (3.8%) of 2033 HIV-positive women in testing for preven-
tion of mother-to-child transmission (PMTCT) services were 
HIV-negative in laboratory tests done for surveillance in 2012 
[10]. A multicountry study using program and surveillance 
reports from testing of pregnant women in programmatic set-
tings yielded estimates for testing algorithm specificity between 
98.5% and 99.5% [11].
Misclassification and unnecessarily treating HIV-negative 
persons has many important ethical, legal, and health system 
consequences. We examined retesting from a purely economic 
perspective; and assessed the cost of retesting before ART initia-
tion compared with the cost saving that could be achieved by not 
providing lifelong ART to misdiagnosed (HIV-negative) persons.
METHODS
We created a simple model to estimate the cost of HIV test-
ing using WHO recommended serial HIV testing strategies, 
the expected number of misclassified HIV-negative persons 
initiated on ART, and the costs of providing lifelong ART to 
misclassified persons. The model is calibrated to reflect the per-
formance of HIV testing algorithms observed in programmatic 
settings and HIV testing and treatment costs in a LMIC (Low 
and Middle Income Countries) setting.
Human Immunodeficiency Virus Testing Assumptions
For an HIV-positive diagnosis, WHO recommends a serial 
testing strategy with at least 2 consecutive positive rapid diag-
nostic tests (RDTs) in high-prevalence settings (>5%) and 3 
consecutive positive RDTs in low-prevalence settings (<5%) 
[5]. Manufacturer specifications stipulating >99% specificity 
for each RDT would ensure at least 99.99% specificity for both 
the 2-test and 3-test strategies if each test were independent 
[12]. To replicate the performance of these testing strategies 
observed in programmatic settings, we assumed 98% specific-
ity for each RDT. Further, we allowed for systematic errors for 
consecutive tests to capture the possibility of correlated human 
errors between otherwise independent RDTs. This is enacted by 
assuming that if the first test misclassified an HIV-negative per-
son as HIV-positive, the subsequent confirmatory test would 
have a 20% chance of also misclassifying the individual (in 
addition to the assumed 98% specificity). Such correlated errors 
could be attributable to environmental conditions or to user 
error affecting the outcome of both tests [13]. Overall, these 
assumptions yielded 99.6% specificity for the 2-test strategy 
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and 99.9% for the 3-test strategy. These levels are consistent 
with or slightly better than the testing algorithm performance 
estimated in the multicountry Centers for Disease Control and 
Prevention (CDC) study [11].
We assumed that retesting by an independent health-worker 
occurs immediately prior to ART initiation using the same 
serial RDT strategies as for primary diagnosis, and that test 
algorithm performance for retesting is the same as for initial 
testing. Finally, we conservatively assume a 5% correlation in 
misclassification at initial testing and at retesting.
Cost Assumptions
We assumed costs representative of typical HIV testing and 
treatment in LMIC settings. For HIV testing, we assumed a 
cost of US$8 for the first RDT irrespective of HIV status. For 
those testing positive, each additional confirmatory RDT and 
associated counseling was US$6 [14]. These were “fully loaded” 
costs representative of low-income settings incorporating the 
costs of commodities, healthcare personnel, supply chain, and 
above-facility management [15].
Conservatively, we assume that costs for retesting are the same 
as in initial testing (first test US$8, each confirmatory test US$6). 
In sensitivity analysis, we alternately assumed that the cost of 
retesting at ART initiation was only the cost of the additional RDT 
kits at US$2 per test, because the additional costs of facilities, per-
sonnel, and counseling are already borne by the ART program.
The annual cost of providing ART was US$450 [16]. We 
assumed a 30-year life expectancy after ART initiation and 
discounted the ART cost by 6% per annum over this period. 
The discounted cost of lifetime ART for a misclassified HIV-
negative person was $6300.
Analysis
We considered HIV testing in 2 settings: one in which HIV 
prevalence is 1% using the serial 3-test strategy, and the second 
with 10% HIV prevalence using the 2-test strategy.
For each setting, in a first scenario (without retesting), 
we calculated the testing cost per 10 000 individuals and the 
expected number of misclassified HIV-negative persons, 
who we assume are initiated on lifelong ART under univer-
sal ART eligibility. In a second scenario (with re-testing), 
we calculated the additional cost of retesting and the num-
ber of individuals who are still misclassified and initiated 
on lifelong ART. We compared the total cost of testing and 
discounted ART costs for misclassified individuals between 
the 2 scenarios. To estimate how long it takes a health sys-
tem to recoup the retesting costs in averted ART costs, we 
calculated the duration within which expected savings from 
averted unnecessary ART provision became greater than the 
cost of retesting before ART initiation. We tested the sensi-
tivity of this outcome to variation in the assumed 98% test 
specificity from 92% to 99%.
RESULTS
In the setting with an HIV prevalence of 1%, testing 10 000 
with the 3-test strategy cost $83 000. Without retesting, 9 HIV-
negative people would be misdiagnosed as positive and initi-
ated on ART for life, costing $58 000 in unnecessary ART costs. 
Retesting all those initially diagnosed HIV-positive would cost 
$2000 and result in an expected 0.03 HIV-negative persons mis-
classified and initiated on ART. This reduced the expected ART 
cost to $186, providing a net saving of $56 000 (Table 1).
For 10% HIV prevalence, using the 2-test strategy to test 
10 000 persons cost $87 000. Without retesting, 39 HIV-
negative people would be misdiagnosed as positive and ini-
tiated on ART with the 2-test strategy, costing $243 000 in 
unnecessary ART costs. Retesting HIV-positive people would 
cost more, $14 000, owing to the larger retesting volume. 
Retesting reduced the number of misclassified HIV-negative 
persons to 0.6 with an expected ART cost to $3628, providing 
net savings of $225 000.
Savings from preventing unnecessary ART outstripped the 
additional expenditure on re-testing within 0.5 years for the 1% 
HIV prevalence scenario and 0.8 years for the 10% HIV preva-
lence scenario. When assuming a lower retesting cost of US$2 
per RDT, savings on ART were greater than retesting costs 
within 0.15 to 0.25 years. The finding that averted ART costs 
quickly overtake retesting costs was robust to a range of val-
ues for the probability of misdiagnosis (Supplementary Figure 
Table  1. Comparison of Retesting Costs and Expected Antiretroviral 
Therapy Costs for Human Immunodeficiency Virus-Negative persons
Low Prevalence 
Example
High Prevalence 
Example
HIV prevalence among testers 1.0% 10.0%
Serial testing strategy 3-test 2-test
Testing strategy specificitya 99.9% 99.6%
Positive predictive value 91.3% 96.2%
Total testing costb $82 628 $87 020
Number of HIV–initiated on ART 9.2 38.9
Expected lifetime ART cost for HIV–c $57 832 $243 399
Retesting specificity 99.7% 98.5%
Positive predictive value (retesting) 99.97% 99.94
Total retesting cost $2011 $14020
HIV–initiated on ART with retesting 0.03 0.6
Expected lifetime ART cost for HIV– $186 $3 628
Expected savings from retesting $55 634 $225 751
Time to recover retesting costs by averted 
ART costs
0.5 y 0.8 y
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; RDT, rapid 
diagnostic tests.
aAssumes a 98% specificity for each serial RDT and allows a correlation such that, if the 
first test was false-positive, the subsequent confirmatory test also had a 20% probability of 
being false-positive due to systemic factors contributing to misdiagnosis.
bUS$8 for the first RDT and $6 for each additional confirmatory RDT and associated 
counseling.
cTotal discounted cost for lifetime ART for an HIV-negative person was $6300.
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S1), suggesting that retesting before ART initiation will likely 
remain cost-saving even as the quality of HIV testing improves.
DISCUSSION
Our estimates suggest that retesting all HIV positive persons 
before ART initiation quickly becomes cost-saving using 
assumptions representative of testing algorithm performance 
and HIV testing and treatment costs typical in LMIC settings. 
This conclusion rests on 2 observations: first the volume of 
retesting is low compared to initial testing because only those 
testing positive are retested; and, second, the high cost of pro-
viding ART care compared to the cost of an HIV test. Overall, in 
both low- and high-HIV prevalence settings the cost of retest-
ing was low compared to the initial testing costs (Table 1) and 
compared to the costs of providing therapeutic ART to diag-
nosed HIV-positive persons.
Although our model representations of HIV testing and ART 
costs are simple, the findings are robust to a range of plausible 
values due to the large difference between the costs of testing 
and the costs of ART. Our assumption that retesting with RDTs 
at the point of ART initiation costs the same as initial testing 
is probably conservative because much of the costs associated 
with testing (health facilities, personnel) are already borne by 
the ART program. The finding that retesting costs are recouped 
within a matter of months or a few years was also robust to a 
range of values for testing algorithm specificity, ART cost, and 
HIV prevalence (Supplementary Appendix S2).
The narrow focus of our retesting analysis on the financial 
and human resource implications to the health system does not 
capture a number of other important factors: the potential eth-
ical, personal, and social consequences of incorrect diagnosis 
and treatment for an HIV-negative person, the quality-of-life 
implications of unneeded regular treatment and potential asso-
ciated toxicities, and the potential undermining effects of mis-
diagnosis for confidence in the health system more widely. For 
these reasons, our analysis of the benefits of retesting is almost 
certainly conservative when considered from a broader societal 
perspective.
Implementation of HIV retesting in specific settings will 
require more detailed analysis using local procurement costs, 
supply chain, and service delivery considerations. However, our 
analysis should motivate national planners and implementing 
partners to carefully consider retesting before ART initiation 
as part of the care package as they develop national strategic 
plans and budgets in response to new universal ART eligibility 
recommendations.
Different retesting approaches could be considered for ver-
ifying diagnoses, including the use of laboratory-based sup-
plementary assays, or point-of-care testing using molecular 
technologies or viral load tests. However, using the same serial 
RDT strategies avoids delays and potential loss to follow-up due 
to transporting specimens and waiting for results from offsite 
laboratories. It also minimizes the need for new equipment, pol-
icies, and staff training that could delay implementation of new 
ART eligibility guidelines. As with all testing, retesting to verify 
diagnosis should undergo routine external quality assurance.
Understanding and addressing reasons for HIV misdiagno-
sis is a public health priority. Meanwhile, countries and imple-
menters should strongly consider routine retesting before ART 
initiation as they formulate national “test-and-offer” guidelines. 
This is a key enabler for robust implementation of new policies, 
is good clinical practice, and is expected to save financial and 
human resources.
Supplementary Data
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